HK1221713A1 - 二羟苯基神经递质化合物、组合物以及方法 - Google Patents

二羟苯基神经递质化合物、组合物以及方法 Download PDF

Info

Publication number
HK1221713A1
HK1221713A1 HK16109787.0A HK16109787A HK1221713A1 HK 1221713 A1 HK1221713 A1 HK 1221713A1 HK 16109787 A HK16109787 A HK 16109787A HK 1221713 A1 HK1221713 A1 HK 1221713A1
Authority
HK
Hong Kong
Prior art keywords
methods
compositions
dihydroxyphenyl
neurotransmitter
compounds
Prior art date
Application number
HK16109787.0A
Other languages
English (en)
Chinese (zh)
Inventor
S. GOLDSTEIN David
Holmes Courtney
Alken Rudolf-Giesbert
Schneider Frank
Zhang Chengzhi
Original Assignee
Auspex Pharmaceuticals, Inc.
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals, Inc., The U.S.A. As Represented By The Secretary, Department Of Health And Human Services filed Critical Auspex Pharmaceuticals, Inc.
Publication of HK1221713A1 publication Critical patent/HK1221713A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16109787.0A 2013-07-08 2014-07-08 二羟苯基神经递质化合物、组合物以及方法 HK1221713A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843549P 2013-07-08 2013-07-08
US61/843,549 2013-07-08
US201462010098P 2014-06-10 2014-06-10
US62/010,098 2014-06-10
PCT/US2014/045731 WO2015006315A1 (en) 2013-07-08 2014-07-08 Dihydroxyphenyl neurotransmitter compounds, compositions and methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
HK42020014008.5A Division HK40022683A (en) 2013-07-08 2016-08-16 Dihydroxyphenyl neurotransmitter compounds, compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42020014008.5A Addition HK40022683A (en) 2013-07-08 2016-08-16 Dihydroxyphenyl neurotransmitter compounds, compositions and methods

Publications (1)

Publication Number Publication Date
HK1221713A1 true HK1221713A1 (zh) 2017-06-09

Family

ID=52133230

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16109787.0A HK1221713A1 (zh) 2013-07-08 2014-07-08 二羟苯基神经递质化合物、组合物以及方法

Country Status (16)

Country Link
US (5) US20150011630A1 (enExample)
EP (2) EP3611159B1 (enExample)
JP (1) JP6567515B2 (enExample)
KR (1) KR20160041912A (enExample)
CN (1) CN105473545B (enExample)
AU (2) AU2014287418A1 (enExample)
BR (1) BR112016000338A8 (enExample)
CA (1) CA2917159C (enExample)
CL (1) CL2016000019A1 (enExample)
EA (1) EA201600093A1 (enExample)
HK (1) HK1221713A1 (enExample)
IL (2) IL243488A0 (enExample)
MX (1) MX384131B (enExample)
PE (1) PE20160556A1 (enExample)
SG (2) SG11201510764QA (enExample)
WO (1) WO2015006315A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238642B2 (en) * 2016-08-30 2019-03-26 Theravance Biopharma R&D Ip, Llc Methods for treating neurogenic orthostatic hypotension
GB2566516A (en) 2017-09-15 2019-03-20 Univ Oxford Innovation Ltd Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3946329A4 (en) 2019-03-27 2022-11-30 Curasen Therapeutics, Inc. BETA ADRENE AGONIST AND METHODS OF USE
AU2020258086A1 (en) 2019-04-17 2021-11-11 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20220401415A1 (en) * 2019-10-25 2022-12-22 Curasen Therapeutics, Inc. Methods for treating neurological disorders with alpha1a-ar partial agonists
WO2021247963A1 (en) * 2020-06-05 2021-12-09 Senda Biosciences, Inc. (s)-alpha-fluoromethyltyrosine as decarboxylase inhibitors for use in the treatment of hypotension

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3360726D1 (en) * 1982-01-14 1985-10-17 Sumitomo Chemical Co Process for producing threo-3-(3,4-dihydroxyphenyl)serine
CA1223602A (en) 1983-05-25 1987-06-30 Naohito Ohashi Process for producing 3-(3,4-dihydroxyphenyl) serine
JP3764179B2 (ja) 1994-07-05 2006-04-05 克寛 西野 運動・意識または言語障害の機能改善剤
DE19619510A1 (de) 1995-05-18 1996-11-21 Sumitomo Chemical Co Verfahren zur Herstellung von Threo-3-(3,4-dihydroxyphenyl)serin
JP3489319B2 (ja) 1996-03-12 2004-01-19 住友化学工業株式会社 カルボン酸誘導体、その製造法および用途
JPH115738A (ja) 1997-06-15 1999-01-12 Katsuhiro Nishino 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
WO2005084330A2 (en) 2004-03-02 2005-09-15 Synergia Pharma, Inc. Compositions and methods for treating nasal congestion
BRPI0708071A8 (pt) * 2006-02-17 2017-12-26 Birds Pharma Gmbh Berolina Innovative Res & Development Services Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos
EP2468271B1 (en) 2007-03-09 2014-07-16 Chelsea Therapeutics, Inc. Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia
EP2142185B1 (en) * 2007-03-12 2012-08-15 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension
AU2008248382B2 (en) 2007-05-07 2013-07-18 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
WO2008151179A2 (en) 2007-06-04 2008-12-11 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
WO2010054286A2 (en) * 2008-11-10 2010-05-14 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
WO2010132128A1 (en) 2009-05-14 2010-11-18 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitve functions in individuals with down syndrome and/or alzheimer's disease
EP2450343A4 (en) 2009-07-01 2013-01-09 Dainippon Sumitomo Pharma Co PROCESS FOR PREPARING THREO-3- (3,4-DIHYDROXYPHENYL) L-SERIN
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US20130253061A1 (en) 2012-03-20 2013-09-26 Chelsea Therapeutics, Inc. Method of droxidopa synthesis

Also Published As

Publication number Publication date
EP3611159B1 (en) 2023-01-25
SG11201510764QA (en) 2016-01-28
BR112016000338A2 (pt) 2017-08-22
CN105473545A (zh) 2016-04-06
HK1216747A1 (zh) 2016-12-02
US20150011630A1 (en) 2015-01-08
KR20160041912A (ko) 2016-04-18
SG10201800166UA (en) 2018-02-27
US20220072131A1 (en) 2022-03-10
US20190374642A1 (en) 2019-12-12
EP3019467A4 (en) 2017-03-15
MX2016000219A (es) 2016-05-31
MX384131B (es) 2025-03-14
WO2015006315A1 (en) 2015-01-15
CA2917159A1 (en) 2015-01-15
AU2014287418A1 (en) 2016-01-28
PE20160556A1 (es) 2016-06-11
US20180280511A1 (en) 2018-10-04
EA201600093A1 (ru) 2016-08-31
AU2018253594A1 (en) 2018-11-22
JP6567515B2 (ja) 2019-08-28
CL2016000019A1 (es) 2016-11-04
CN105473545B (zh) 2017-08-04
IL266767A (en) 2019-07-31
JP2016529228A (ja) 2016-09-23
IL243488A0 (en) 2016-02-29
EP3611159A1 (en) 2020-02-19
BR112016000338A8 (pt) 2020-01-07
CA2917159C (en) 2022-08-23
US20170319694A1 (en) 2017-11-09
EP3019467A1 (en) 2016-05-18

Similar Documents

Publication Publication Date Title
EP3102670A4 (en) Systems, methods, and compositions relating to combiomics
EP3060041A4 (en) Prostacyclin compounds, compositions and methods of use thereof
EP3186277A4 (en) Antibodies, compositions, and uses
HK1216859A1 (zh) Irak抑制劑和其用途
AU2018253594A1 (en) Dihydroxyphenyl neurotransmitter compounds, compositions and methods
WO2014194117A3 (en) Novel metalloproteases
EP3035936A4 (en) Certain chemical entities, compositions, and methods
EP3082819A4 (en) Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
EP3157515A4 (en) Platinum compounds, compositions, and uses thereof
HK1217410A1 (zh) Erk抑制劑及其用途
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
EP3140305A4 (en) Novel compositions, uses and methods for making them
EP3133152A4 (en) Novel bacteriophage, and composition containing same
EP3041841A4 (en) Triazolopyridine compounds, compositions and methods of use thereof
EP3223820A4 (en) C5-c6-oxacyclic fused iminopyrimidinone compounds as bace inhibitors, compositions, and their use
WO2014107596A8 (en) Compositions and methods for polynucleotide transfection
EP3207149A4 (en) Pharmaceutical composition with improved stability
IL248783A0 (en) Fluorescence quenching compounds, preparations containing them and their uses
EP3313393A4 (en) PLATINUM COMPOUNDS, COMPOSITIONS, AND USES THEREOF
WO2013190274A3 (en) Biodegradable compositions
EP3153492A4 (en) Novel compound and fragrance composition containing same
HK1221645A1 (zh) Vmat2的苯并喹啉抑制剂
EP3135663A4 (en) Novel compound, and flavor composition containing said compound
HK1223300A1 (zh) 皮质类固醇组合物
WO2016109361A3 (en) 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase